LTR Pharma (ASX:LTP) FCF Yield % : -5.46 (As of Mar. 24, 2025)

View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, LTR Pharma's Trailing 12-Month Free Cash Flow is A$-5.29 Mil, and Market Cap is A$96.82 Mil. Therefore, LTR Pharma's FCF Yield % for today is -5.46%.

The historical rank and industry rank for LTR Pharma's FCF Yield % or its related term are showing as below:

ASX:LTP' s FCF Yield % Range Over the Past 10 Years
Min: -5.67 Med: 0 Max: 0
Current: -5.46

ASX:LTP's FCF Yield % is ranked better than
67.24% of 1502 companies
in the Biotechnology industry
Industry Median: -14.3 vs ASX:LTP: -5.46

LTR Pharma's FCF Margin % for the quarter that ended in Dec. 2024 was -3,812.70%.

LTR Pharma FCF Yield % Historical Data

The historical data trend for LTR Pharma's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma FCF Yield % Chart

LTR Pharma Annual Data

Trend

Jun21

Jun22

Jun23

Jun24

FCF Yield %

-4.69

LTR Pharma Semi-Annual Data
	Jun21	Jun22	Jun23	Dec23	Jun24	Dec24
FCF Yield %	Get a 7-Day Free Trial			-	-	-9.17	-5.31	-3.28

Competitive Comparison of LTR Pharma's FCF Yield %

For the Biotechnology subindustry, LTR Pharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LTR Pharma's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LTR Pharma's FCF Yield % distribution charts can be found below:

* The bar in red indicates where LTR Pharma's FCF Yield % falls into.

LTR Pharma FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

LTR Pharma's FCF Yield % for the fiscal year that ended in Jun. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-5.095	/	108.7476
	=	-4.69%

LTR Pharma's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-2.402	*	2	/	146.59218
	=	-3.28%

LTR Pharma FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

LTR Pharma FCF Yield % Related Terms

Thank you for viewing the detailed overview of LTR Pharma's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

LTR Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

9A/204 Alice Street, Brisbane, QLD, AUS, 4000

Website

https://www.ltrpharma.com

LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.

LTR Pharma Headlines

No Headlines